Physician profile
Thomas R Carn
NPI 1194774588
$5,910.99
in general payments reported to CMS, 2019-2025
38 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $674 · 2021: $1,169 · 2022: $930 · 2023: $1,124 · 2024: $933 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $936.04 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $797.53 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $761.55 | 2020-2025 | Vraylar, Ubrelvy, Liletta |
| Astrazeneca Pharmaceuticals LP | $463.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $429.52 | 2019-2025 | Evenity, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $377.76 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Novo Nordisk INC | $347.60 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $317.40 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $224.43 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $211.29 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $138.21 | 2020-2024 | Xarelto |
| Sanofi Pasteur INC. | $116.85 | 2021-2025 | |
| Abbott Laboratories | $83.08 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.38 | 2019-2024 | |
| Amarin Pharma, INC. | $63.04 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $58.40 | 2024-2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $44.36 | 2020 | |
| Exact Sciences Corporation | $42.01 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $35.79 | 2022 | |
| Idorsia Pharmaceuticals US INC | $35.38 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $31.08 | 2021 | |
| Antares Pharma, INC. | $26.05 | 2019 | |
| Bausch Health US, LLC | $25.60 | 2022 | |
| Edwards Lifesciences Corporation | $25.58 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Vanda Pharmaceuticals INC. | $23.84 | 2024 | Fanapt |
| Eisai INC. | $22.95 | 2021 | |
| Ani Pharmaceuticals, INC. | $22.25 | 2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $20.29 | 2025 | Wavewriter Alpha Prime 16 |
| Corium, LLC | $19.22 | 2025 | Azstarys |
| Organon LLC | $18.87 | 2025 | Nexplanon |
| Allergan, INC. | $18.67 | 2020 | |
| Seqirus USA INC | $18.39 | 2022 | |
| Inspire Medical Systems, INC. | $15.89 | 2025 | Inspire |
| Lucid Diagnostics INC. | $15.82 | 2023 | |
| Dexcom, INC. | $15.69 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $15.28 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.52 | 2022 | |
| Sumitomo Pharma America, INC. | $10.64 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Carn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.